TY  - JOUR
AU  - Treem, William R
AU  - Palmer, Melissa
AU  - Lonjon-Domanec, Isabelle
AU  - Seekins, Daniel
AU  - Dimick-Santos, Lara
AU  - Avigan, Mark I
AU  - Marcinak, John F
AU  - Dash, Ajit
AU  - Regev, Arie
AU  - Maller, Eric
AU  - Patwardhan, Meenal
AU  - Lewis, James H
AU  - Rockey, Don C
AU  - Di Bisceglie, Adrian M
AU  - Freston, James W
AU  - Andrade, Raul J
AU  - Chalasani, Naga
PY  - 2020
DO  - 10.1007/s40264-020-01014-2
UR  - http://hdl.handle.net/10668/16535
T2  - Drug safety
AB  - With the widespread development of new drugs to treat chronic liver diseases (CLDs), including viral hepatitis and nonalcoholic steatohepatitis (NASH), more patients are entering trials with abnormal baseline liver tests and with advanced liver...
LA  - en
KW  - Adult
KW  - Chemical and Drug Induced Liver Injury
KW  - Clinical Trials as Topic
KW  - Consensus
KW  - Hepatitis B
KW  - Hepatitis C
KW  - Hepatitis, Chronic
KW  - Humans
KW  - Liver Cirrhosis
KW  - Non-alcoholic Fatty Liver Disease
KW  - Practice Guidelines as Topic
TI  - Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
TY  - research article
VL  - 44
ER  -